Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Demographic and disease-related factors impact on cerebrospinal fluid neurofilament light chain levels in multiple sclerosis

K. Zondra Revendova, C. Starvaggi Cucuzza, A. Manouchehrinia, M. Khademi, M. Bar, D. Leppert, E. Sandberg, R. Ouellette, T. Granberg, F. Piehl

. 2023 ; 13 (1) : e2873. [pub] 20221227

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc23004720

BACKGROUND: Neurofilament light (NfL) levels reflect inflammatory disease activity in multiple sclerosis (MS), but it is less clear if NfL also can serve as a biomarker for MS progression in treated patients without relapses and focal lesion accrual. In addition, it has not been well established if clinically effective treatment re-establishes an age and sex pattern for cerebrospinal fluid NfL (cNfL) as seen in controls, and to what degree levels are affected by disability level and magnetic resonance imaging (MRI) atrophy metrics. METHODS: We included subjects for whom cNfL levels had been determined as per clinical routine or in clinical research, classified as healthy controls (HCs, n = 89), MS-free disease controls (DCs, n = 251), untreated MS patients (uMS; n = 296), relapse-free treated MS patients (tMS; n = 78), and ProTEct-MS clinical trial participants (pMS; n = 41). RESULTS: Using linear regression, we found a positive association between cNfL and age, as well as lower concentrations among women, in all groups, except for uMS patients. In contrast, disability level in the entire MS cohort, or T1 and T2 lesion volumes, brain parenchymal fraction, thalamic fraction, and cortical thickness in the pMS trial cohort, did not correlate with cNfL concentrations. Furthermore, the cNfL levels in tMS and pMS groups did not differ. CONCLUSIONS: In participants with MS lacking signs of inflammatory disease activity, disease modulatory therapy reinstates an age and sex cNfL pattern similar to that of control subjects. No significant association was found between cNfL levels and clinical worsening, disability level, or MRI metrics.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23004720
003      
CZ-PrNML
005      
20230425171659.0
007      
ta
008      
230418s2023 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/brb3.2873 $2 doi
035    __
$a (PubMed)36573731
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Zondra Revendova, Kamila $u Centre for Molecular Medicine, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden $u Centre for Neurology, Academic Specialist Center, Karolinska University Hospital, Stockholm, Sweden $u Department of Clinical Neurosciences, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic $1 https://orcid.org/0000000331833526
245    10
$a Demographic and disease-related factors impact on cerebrospinal fluid neurofilament light chain levels in multiple sclerosis / $c K. Zondra Revendova, C. Starvaggi Cucuzza, A. Manouchehrinia, M. Khademi, M. Bar, D. Leppert, E. Sandberg, R. Ouellette, T. Granberg, F. Piehl
520    9_
$a BACKGROUND: Neurofilament light (NfL) levels reflect inflammatory disease activity in multiple sclerosis (MS), but it is less clear if NfL also can serve as a biomarker for MS progression in treated patients without relapses and focal lesion accrual. In addition, it has not been well established if clinically effective treatment re-establishes an age and sex pattern for cerebrospinal fluid NfL (cNfL) as seen in controls, and to what degree levels are affected by disability level and magnetic resonance imaging (MRI) atrophy metrics. METHODS: We included subjects for whom cNfL levels had been determined as per clinical routine or in clinical research, classified as healthy controls (HCs, n = 89), MS-free disease controls (DCs, n = 251), untreated MS patients (uMS; n = 296), relapse-free treated MS patients (tMS; n = 78), and ProTEct-MS clinical trial participants (pMS; n = 41). RESULTS: Using linear regression, we found a positive association between cNfL and age, as well as lower concentrations among women, in all groups, except for uMS patients. In contrast, disability level in the entire MS cohort, or T1 and T2 lesion volumes, brain parenchymal fraction, thalamic fraction, and cortical thickness in the pMS trial cohort, did not correlate with cNfL concentrations. Furthermore, the cNfL levels in tMS and pMS groups did not differ. CONCLUSIONS: In participants with MS lacking signs of inflammatory disease activity, disease modulatory therapy reinstates an age and sex cNfL pattern similar to that of control subjects. No significant association was found between cNfL levels and clinical worsening, disability level, or MRI metrics.
650    _2
$a lidé $7 D006801
650    _2
$a ženské pohlaví $7 D005260
650    12
$a roztroušená skleróza $x diagnostické zobrazování $7 D009103
650    _2
$a intermediární filamenta $x patologie $7 D007382
650    _2
$a biologické markery $x mozkomíšní mok $7 D015415
650    _2
$a magnetická rezonanční tomografie $7 D008279
650    _2
$a demografie $7 D003710
650    12
$a relabující-remitující roztroušená skleróza $7 D020529
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Starvaggi Cucuzza, Chiara $u Centre for Molecular Medicine, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden $u Centre for Neurology, Academic Specialist Center, Karolinska University Hospital, Stockholm, Sweden $1 https://orcid.org/0000000290887658
700    1_
$a Manouchehrinia, Ali $u Centre for Molecular Medicine, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
700    1_
$a Khademi, Mohsen $u Centre for Molecular Medicine, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
700    1_
$a Bar, Michal $u Department of Clinical Neurosciences, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
700    1_
$a Leppert, David $u Neurologic Clinic and Policlinic, MS Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), Basel, Switzerland
700    1_
$a Sandberg, Elisabeth $u Department of Neuroradiology, Karolinska University Hospital, Stockholm, Sweden
700    1_
$a Ouellette, Russell $u Department of Neuroradiology, Karolinska University Hospital, Stockholm, Sweden
700    1_
$a Granberg, Tobias $u Department of Neuroradiology, Karolinska University Hospital, Stockholm, Sweden
700    1_
$a Piehl, Fredrik $u Centre for Molecular Medicine, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden $u Centre for Neurology, Academic Specialist Center, Karolinska University Hospital, Stockholm, Sweden
773    0_
$w MED00188000 $t Brain and behavior $x 2162-3279 $g Roč. 13, č. 1 (2023), s. e2873
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36573731 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230418 $b ABA008
991    __
$a 20230425171655 $b ABA008
999    __
$a ok $b bmc $g 1925045 $s 1190929
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 13 $c 1 $d e2873 $e 20221227 $i 2162-3279 $m Brain and behavior $n Brain Behav $x MED00188000
LZP    __
$a Pubmed-20230418

Najít záznam

Citační ukazatele

Možnosti archivace